4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 94 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2023. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $8,594,931 | -22.6% | 499,996 | 0.0% | 1.24% | -28.5% |
| Q4 2022 | $11,104,911 | +176.2% | 499,996 | 0.0% | 1.73% | +149.1% |
| Q3 2022 | $4,020,000 | -9.0% | 499,996 | -21.0% | 0.69% | -41.1% |
| Q2 2022 | $4,417,000 | -81.4% | 632,745 | -59.6% | 1.18% | -77.0% |
| Q1 2022 | $23,691,000 | -30.4% | 1,566,895 | +1.0% | 5.12% | -22.7% |
| Q4 2021 | $34,030,000 | +51.8% | 1,551,070 | +86.6% | 6.62% | +20.0% |
| Q3 2021 | $22,419,000 | +12.0% | 831,267 | 0.0% | 5.52% | +33.1% |
| Q2 2021 | $20,017,000 | +22.0% | 831,267 | +119.7% | 4.15% | -32.9% |
| Q1 2021 | $16,410,000 | +4.8% | 378,288 | +0.1% | 6.18% | +13.9% |
| Q4 2020 | $15,659,000 | – | 377,777 | – | 5.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |